{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T12:12:56Z","timestamp":1778501576075,"version":"3.51.4"},"reference-count":31,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"vor","delay-in-days":41,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["A&amp;amp;D Transl Res &amp;amp; Clin Interv"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:label\/>\n                    <jats:p>The design of clinical trials in Alzheimer's disease (AD) must consider the development of new plasma, cerebrospinal fluid (CSF), and imaging biomarkers. They must also define clinically meaningful outcomes for patients and set endpoints that measure these outcomes accurately. With the accelerated United States Food and Drug Administration (FDA) approval of the first anti\u2010amyloid, disease\u2010modifying treatment for AD, a monoclonal antibody called aducanumab, the landscape of clinical trial design is evolving. Enrolment in clinical trials may be impacted by the availability of this and other treatments, and trial design must take into consideration that patients may desire a disease\u2010modifying treatment rather than potentially being randomized to the placebo arm. The Alzheimer's Association Research Roundtable (AARR) Fall 2021 meeting discussed the consideration of well\u2010defined AD staging criteria in protocol design and how they influence more standardized inclusion\/exclusion criteria for trials, as well as what constitutes meaningful differentiation between the stages. Discussion explored the current state of knowledge regarding biomarkers and how they can inform AD staging criteria, as many trials are now designed based on specific biomarker features, further underscoring the importance of coordinating AD staging criteria and biomarkers. The relationship between cognition and biomarkers has been studied and this must continue as trials move forward. Researchers, patients, clinicians, regulatory scientists, and payers discussed the state of the field as well as the future of symptomatic Alzheimer's disease clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Highlights<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>The Alzheimer's Association Research Roundtable (AARR) convened leaders from academia and industry as well as patients, care partners, clinicians, regulators, and payers to discuss the topic of operationalizing selection criteria for clinical trials and the role of biomarkers.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Well\u2010defined Alzheimer's disease (AD) staging criteria are an important consideration in study protocol design.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Staging criteria and biomarkers must be coordinated to yield high\u2010quality clinical trial results that have meaning for patients with AD by selecting a population most likely to benefit from a specific treatment.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/trc2.70038","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T09:09:17Z","timestamp":1739264957000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Operationalizing selection criteria for clinical trials in Alzheimer's disease: Biomarker and clinical considerations: Proceedings from the Alzheimer's Association Research Roundtable (AARR) Fall 2021 meeting"],"prefix":"10.1002","volume":"11","author":[{"given":"Ronald C.","family":"Petersen","sequence":"first","affiliation":[{"name":"Department of Neurology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Graf","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG  Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Brady","sequence":"additional","affiliation":[{"name":"WCG Clinical Endpoint Solutions Princeton  New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"De Santi","sequence":"additional","affiliation":[{"name":"Neurology Business Group Eisai  Nutley New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana","family":"Florian","sequence":"additional","affiliation":[{"name":"Dept R48B Abbvie Bldg AP32  North Chicago Illinois USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaren","family":"Landen","sequence":"additional","affiliation":[{"name":"Biogen  Cambridge Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mike","family":"Pontecorvo","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Randolph","sequence":"additional","affiliation":[{"name":"WCG Clinical Endpoint Solutions Princeton  New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaycee","family":"Sink","sequence":"additional","affiliation":[{"name":"Genentech Inc  South San Francisco California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Carrillo","sequence":"additional","affiliation":[{"name":"Alzheimer's Association  Chicago Illinois USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Weber","sequence":"additional","affiliation":[{"name":"Alzheimer's Association  Chicago Illinois USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,2,11]]},"reference":[{"key":"e_1_2_6_2_1","unstructured":"Food and Drug Administration.FDA News Release: FDA Grants Accelerated Approval for Alzheimer's Drug [Internet].2021.https:\/\/www.fda.gov\/news\u2010events\/press\u2010announcements\/fda\u2010grants\u2010accelerated\u2010approval\u2010alzheimers\u2010drug"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.30"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010023\u201001938\u2010w"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.02.018"},{"key":"e_1_2_6_6_1","unstructured":"Patient\u2010Focused Drug Development: Collecting comprehensive and representative input. Guidance for industry Food and Drug Administration staff and other stakeholders [Internet].2018[cited 2019 Dec 17].https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/patientfocused\u2010drug\u2010development\u2010collecting\u2010comprehensive\u2010and\u2010representative\u2010input"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-021-01263-2"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12756"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12181"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474\u20104422(20)30440\u20103"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trci.2019.09.018"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202114408"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9030252"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2019.08.201"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bionps.2019.100005"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.1858"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2100708"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/nn.4018"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41583\u2010021\u201000533\u2010w"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph14090928"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12073"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012329"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012329"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474\u20104422(21)00237\u20104"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000200604"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/cercor\/bhab017"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.20.2701"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/15265161.2020.1863511"},{"key":"e_1_2_6_29_1","unstructured":"https:\/\/www.aafp.org\/about\/policies\/all\/primary\u2010care.html"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13244"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011214"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12226"}],"container-title":["Alzheimer's &amp; Dementia: Translational Research &amp; Clinical Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/trc2.70038","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:17:28Z","timestamp":1761491848000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1002\/trc2.70038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1002\/trc2.70038"],"URL":"https:\/\/doi.org\/10.1002\/trc2.70038","archive":["Portico"],"relation":{},"ISSN":["2352-8737","2352-8737"],"issn-type":[{"value":"2352-8737","type":"print"},{"value":"2352-8737","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"2024-07-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70038"}}